Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Compare CAR-T CDMOs in USA
Compare Cell Therapy CDMOs in USA
Compare Gene Editing CDMOs in USA
Compare Plasmid DNA CDMOs in USA
Compare AAV CDMOs in USA
Compare Lentiviral CDMOs in USA
Compare ADC CDMOs in USA
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
86.3
Signal Score
✓ FDA Inspections (9)
○ Clinical Trials
✓ SEC Filings (19)
✓ Press (20)
✓ EMA GMP (9)
✓ MHRA GMP (2)
✓ HC GMP (30)
Quick Facts: Charles River Laboratories
- Signal Score
- 86.3/100 (as of 2026-10-29)
- Quality Compliance
- 99.2/100 — Clean EMA record: 9 active GMP certificates (no deductions)
- Headquarters
- Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
- Modalities
- CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
- Active Programs
- No ClinicalTrials.gov matches confirmed — 5 partnership signals in press (announcements, not verified)
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Charles River Laboratories
Sold its cell and gene therapy CDMO (formerly Cognate, Cobra Biologics and Vigene Biosciences) and Cell Solutions businesses to GI Partners in May 2026; they now operate as Rose BioSolutions.
Signal Score & Pillar Breakdown
Quality Compliance
99.2
Clean EMA record: 9 active GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP, MHRA GMDP
Clean EMA record: 9 active GMP certificates (no deductions)
FDA Inspections9 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2026-05-01)
EMA GMP Certificates9 on record
MHRA GMP Certificates2 on record
Most Recent HC OutcomeCompliant · 2026-02-19
HC Attribution30 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Clean EMA record: 9 active GMP certificates (no deductions)
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 5 partnership announcements found in press monitoring.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Partnership Signals (from press monitoring)
Company announcements, not verified evidence.
Financial Stability
75.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
19 SEC filings with industry mentions on record (shown, not scored)
SEC Filings19 with industry mentions (not scored)
Publicly traded — financial transparency
Capacity
75.0
Multi-site operations (5 manufacturing sites)
Broad modality coverage (7 modalities)
Sites: Newbury Park, CA, Memphis, TN, Mattawan, MI, Keele, UK, Rockville, MD
Source: company profiles (manufacturing sites, modality breadth)
5 manufacturing sites
StatusLimited
Multi-site operations (5 manufacturing sites)
Broad modality coverage (7 modalities)
Sites: Newbury Park, CA, Memphis, TN, Mattawan, MI, Keele, UK, Rockville, MD
Press Signals20 articles (not scored)
Multi-site operations (5 manufacturing sites)
Broad modality coverage (7 modalities)
Charles River Laboratories FDA Inspection History
2026-05
2026-04
2026-03
2026-01
2025-09
2025-09
2025-05
2024-01
2022-11
NAI
VAI
OAI
| Date | Site | Type | 483 citations posted | Classification |
|---|---|---|---|---|
| 2026-05-01 |
Charles River Laboratories, Inc.
Saint-Laurent
Facility-linked
|
Bioresearch Monitoring | Not posted | No Action Indicated (NAI) |
| 2026-04-02 |
CHARLES RIVER LABORATORIES
Wayne, Pennsylvania
Facility-linked
|
Drug Quality Assurance | Not posted | No Action Indicated (NAI) |
| 2026-03-27 |
Charles River Laboratories, Inc.
Charleston, South Carolina
Facility-linked
|
Drug Quality Assurance | Yes | Voluntary Action Indicated (VAI) |
| 2026-01-20 |
Charles River Laboratories, Inc.
Malvern, Pennsylvania
Facility-linked
|
Drug Quality Assurance | Not posted | No Action Indicated (NAI) |
| 2025-09-17 |
Charles River Laboratories, Inc.
Shrewsbury, Massachusetts
Facility-linked
|
Drug Quality Assurance | Not posted | No Action Indicated (NAI) |
| 2025-09-09 |
Charles River Laboratories, Inc.
Wilmington, Massachusetts
Facility-linked
|
Drug Quality Assurance | Yes | Voluntary Action Indicated (VAI) |
| 2025-05-02 |
Charles River Laboratories, Inc.
Wilmington, Massachusetts
Facility-linked
|
Vaccines and Allergenic Products | Not posted | No Action Indicated (NAI) |
| 2024-01-04 |
Charles River Laboratories, Inc.
Malvern, Pennsylvania
Facility-linked
|
Drug Quality Assurance | Yes | Voluntary Action Indicated (VAI) |
| 2022-11-09 |
CHARLES RIVER LABORATORIES
Wayne, Pennsylvania
Facility-linked
|
Drug Quality Assurance | Not posted | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Nov 21, 2026
Charles River Laboratories FDA 483 Findings 4 observations · 2024-01-04 → 2026-03-27 ?
By subsystem
By severity
- 3 — Moderate: 2
- 2 — Minor: 2
- Repeat observations: 0
Most severe findings
-
Written record of investigation incomplete
"Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up."
-
Investigations of discrepancies, failures
"There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed."
-
Procedures not in writing, fully followed
"The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed."
Charles River Laboratories EMA GMP Compliance 9 certificates
2025-08
2025-08
2025-04
2025-04
2025-04
2022-07
2022-07
2022-07
2022-07
Compliant
Non-Compliant
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| DE_NW_06_GMP_2025_0010 | Charles River Laboratories Germany GmbH | Germany | 2025-08-20 | COMPLIANT |
| DE_NW_03_GMP_2025_0098 | Charles River Laboratories Germany GmbH | Germany | 2025-08-20 | COMPLIANT |
| 35848/QCLab12286(H) | Charles River Laboratories Ireland Limited | Ireland | 2025-04-10 | COMPLIANT |
| 35848/QCLab12286(V) | Charles River Laboratories Ireland Limited | Ireland | 2025-04-10 | COMPLIANT |
| 35848/QCLab12286(IMP) | Charles River Laboratories Ireland Limited | Ireland | 2025-04-10 | COMPLIANT |
| 2022_HPF_FR_179 | Charles River Laboratories France C.R.L.F. | France | 2022-07-22 | COMPLIANT |
| 2022_HPF_FR_180_P_2025 | Charles River Laboratories France C.R.L.F. | France | 2022-07-22 | COMPLIANT |
| 2022_HPF_FR_180 | Charles River Laboratories France C.R.L.F. | France | 2022-07-22 | COMPLIANT |
| 2022_HPF_FR_179_P_2025 | Charles River Laboratories France C.R.L.F. | France | 2022-07-22 | COMPLIANT |
Source: EMA EudraGMDP · Retrieved Nov 21, 2026
Charles River Laboratories MHRA GMP Compliance 2 certificates
2019-11
2019-11
Compliant
Non-Compliant
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK GMP 24616 Insp GMP/IMP 24616/25448-0034 [H] | CHARLES RIVER LABORATORIES EDINBURGH LIMITED | TRANENT EH33 2NE | 2019-11-21 | COMPLIANT |
| UK GMP 24616 Insp GMP/IMP 24616/25448-0034 [V] | CHARLES RIVER LABORATORIES EDINBURGH LIMITED | TRANENT EH33 2NE | 2019-11-21 | COMPLIANT |
Source: MHRA GMDP Database · Retrieved Nov 21, 2026
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No count for this company yet. The careers board we can read covers more than this business (387 postings on Nov 20, 2026), and we can't yet tell which of those roles belong to it. Why: Charles River's careers board covers the whole company, mostly research models, safety testing and lab services. We can't reliably pick out the roles at its contract-manufacturing sites. We'd rather show no number than one that isn't really this company's.
Source:
careers.criver.com
· Checked Nov 20, 2026
Financial Intelligence
"Item 7.01 Regulation FD Disclosure: On September 24, 2026, in connection with its Investor Day, Charles River Laboratories International, Inc. (the “Company”) issued a press release that, among other things, discusses its business strategy, reaffirms its full-year 2026 guidance, and provides its long-term financial targets through 2030. A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated by reference herein."
"crl-20260627
0001100682
12/26
2026
Q2
false
P11Y
365
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
crl:segment
xbrli:pure
0001100682
2025-12-28
2026-06-27
0001100682
2026-07-25
0001100682
us-gaap:ServiceMember
2026-03-29
2026-06-27
0001100682
us-gaap:ServiceMember
2025-03-30
2025-06-28
0001100682
us-gaap:ServiceMember
2025-12-28
2026-06-27
0001100682
us-gaap:ServiceMember
2024-12-29
2025-06-28
0001100682
us-gaap:ProductMember
2026-03-29
2026-06-27
0001100682
us-gaap:ProductMember
2025-03-30
"
"In May 2026, the Company sold the contract development and manufacturing products and services (CDMO) business, reported in the Manufacturing segment."
"Divestiture of CDMO and Cell Solutions
On May 6, 2026, the Company sold its CDMO and Cell Solutions businesses (CDMO and Cell Solutions Divestiture) to GI Partners (GI) for net cash paid to the buyer of $
12.4
million, net of costs to sell and subject to certain customary closing adjustments."
"Item 2.02 Results of Operations and Financial Condition: The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."
"Item 5.02 Departure of Directors or Certain Officers; Election of: Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers."
"Item 5.07 Submission of Matters to a Vote of Security Holders: At the Company’s Annual Meeting, the following proposals were"
"crl-20260328
0001100682
12/26
2026
Q1
false
P11Y
333
824
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
crl:segment
xbrli:pure
iso4217:EUR
0001100682
2025-12-28
2026-03-28
0001100682
2026-04-24
0001100682
us-gaap:ServiceMember
2025-12-28
2026-03-28
0001100682
us-gaap:ServiceMember
2024-12-29
2025-03-29
0001100682
us-gaap:ProductMember
2025-12-28
2026-03-28
0001100682
us-gaap:ProductMember
2024-12-29
2025-03-29
0001100682
2024-12-29
2025-03-29
0001100682
2026-03-28
0001100682
2025-12-27
000110"
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Divestiture of CDMO and Cell Solutions
On May 6, 2026, the Company completed the sale of its CDMO and Cell Solutions businesses (CDMO and Cell Solutions Divestiture) to GI Partners (GI) for future contingent performance-based payments up to $
50.0
million, subject to certain customary closing adjustments."
"Item 2.02 Results of Operations and Financial Condition: The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."
"Planned Divestiture of CDMO and Cell Solutions Businesses
On February 25, 2026, Charles River Laboratories International, Inc."
"(the “Company”) announced that it has signed a definitive agreement to divest its contract development and manufacturing products and services (“CDMO”) and Cell Solutions businesses to GI Partners, primarily for future, contingent performance-based payments."
"The CDMO business provides services related to the production of advanced therapies for gene-modified cell therapies, as well as gene therapies including viral vectors and plasmid DNA; and the Cell Solutions business provides human-derived cellular materials used in the development and production of cell therapies."
"Our client base includes major global pharmaceutical companies, many biotechnology companies;
agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies
around the world."
"We have extensive expertise in the discovery of clinical candidates and in the design, execution and reporting of safety assessment studies for numerous types of therapeutic modalities, including cell and gene therapies, small and large molecule pharmaceuticals, industrial and agricultural chemicals, vaccines, consumer products, veterinary medicines, biocides and medical devices."
"Biologics Solutions is comprised of both our Biologics Testing Solutions business, which provides specialized testing of biologics frequently outsourced by global pharmaceutical and biotechnology companies, and our contract development and manufacturing products and services (“CDMO”) business, which provides comprehensive contract development and manufacturing solutions for cell and gene therapies."
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"The decrease in intangible assets for the nine months ended September 27, 2025 related primarily to the accelerated amortization of certain CDMO client relationships in the Biologics Solutions reporting unit, normal amortization over the useful lives, and a divestiture of a site in the DSA reportable segment."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"The decrease in intangible assets for the six months ended June 28, 2025 related primarily to the accelerated amortization of certain CDMO client relationships in the Biologics Solutions reporting unit, normal amortization over the useful lives, and a divestiture of a site in the DSA reportable segment."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"The decrease in intangible assets for the three months ended March 29, 2025 related primarily to the accelerated amortization of certain CDMO client relationships in the Biologics Solutions reporting unit, normal amortization over the useful lives, and a divestiture of a site in the DSA reportable segment."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"Our client base includes major global pharmaceutical companies, many biotechnology companies;
agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies
around the world."
"We have extensive expertise in the discovery of clinical candidates and in the design, execution and reporting of safety assessment studies for numerous types of therapeutic modalities, including cell and gene therapies, small and large molecule pharmaceuticals, industrial and agricultural chemicals, vaccines, consumer products, veterinary medicines, biocides and medical devices."
"Biologics Solutions is comprised of both our Biologics Testing Solutions business, which provides specialized testing of biologics frequently outsourced by global pharmaceutical and biotechnology companies, and our contract development and manufacturing products and services (“CDMO”) business, which provides comprehensive contract development and manufacturing solutions for cell and gene therapies."
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"Our Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Attorney’s Office for the Southern District of Florida that a Cambodian non-human primate supplier and two Cambodian officials had been criminally charged in connection with illegally importing non-human primates into the United States; client demand, particularly future demand for drug discovery and development products and services, including the outsourcing of these services; our expectations with respect to our ability to meet financial targets; our expectations regarding stock repurchases, "
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
(non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"Attorney’s Office for the Southern District of Florida that a Cambodian non-human primate supplier and two Cambodian officials had been criminally charged in connection with illegally importing non-human primates into the United States; client demand, particularly future demand for drug discovery and development products and services, including the outsourcing of these services; our expectations with respect to our ability to meet financial targets; our expectations regarding stock repurchases, "
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
(non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
Source: SEC EDGAR · Retrieved Nov 21, 2026
Company Signals 20 articles
Company announcements, not verified evidence. They do not change any score.
Does FDA Drug Testing Partnership Change The Bull Case For Charles River Labs Stock? - Simply Wall St
Does FDA Drug Testing Partnership Change The Bull Case For Charles River Labs Stock? Simply Wall St
Drug Development Inputs & Services Stocks Q2 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers - TradingView
Drug Development Inputs & Services Stocks Q2 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers TradingView
Charles River partners with Magellan Stem Cells on cell therapy - Yahoo Finance
Charles River partners with Magellan Stem Cells on cell therapy Yahoo Finance
Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development - Business Wire
Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development Business Wire
Charles River and Autolomous launch Apollo Orchestrate LES to digitalise biologics QC testing workflow - Manufacturing Chemist
Charles River and Autolomous launch Apollo Orchestrate LES to digitalise biologics QC testing workflow Manufacturing Chemist
Charles River and Autolomous Partner to Transform Laboratory Execution Systems - Business Wire
Charles River and Autolomous Partner to Transform Laboratory Execution Systems Business Wire
NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs - Yahoo Finance
NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs Yahoo Finance
Charles River Laboratories Stock: Q1 2026 Earnings Release Scheduled for April 30 - AD HOC NEWS
Charles River Laboratories Stock: Q1 2026 Earnings Release Scheduled for April 30 AD HOC NEWS
Charles River Laboratories stock (US1591881009): Why Google Discover changes matter more now - AD HOC NEWS
Charles River Laboratories stock (US1591881009): Why Google Discover changes matter more now AD HOC NEWS
Charles River Laboratories stock (US1591881009): Is its drug discovery dominance strong enough to un - AD HOC NEWS
Charles River Laboratories stock (US1591881009): Is its drug discovery dominance strong enough to un AD HOC NEWS
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Pack - TradingView
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Pack TradingView
A Review of Q4 Earnings for Drug Development Inputs & Services Stocks: Comparing Charles River Laboratories (NYSE:CRL) with Its Peers - Bitget
A Review of Q4 Earnings for Drug Development Inputs & Services Stocks: Comparing Charles River Laboratories (NYSE:CRL) with Its Peers Bitget
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Pack - StockStory
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Pack StockStory
A Review of Q4 Earnings for Drug Development Inputs & Services Stocks: Comparing Charles River Laboratories (NYSE:CRL) with Its Peers - Bitget
A Review of Q4 Earnings for Drug Development Inputs & Services Stocks: Comparing Charles River Laboratories (NYSE:CRL) with Its Peers Bitget
Charles River Laboratories parts ways with its CDMO business - European Pharmaceutical Review
Charles River Laboratories parts ways with its CDMO business European Pharmaceutical Review
Charles River Laboratories to divest a number of assets to IQVIA and GI Partners - Business Weekly
Charles River Laboratories to divest a number of assets to IQVIA and GI Partners Business Weekly
Charles River Laboratories Provides Update on Planned Divestitures - Business Wire
Charles River Laboratories Provides Update on Planned Divestitures Business Wire
Charles River Laboratories to divest CDMO, Cell Solutions, and European assets - Investing.com
Charles River Laboratories to divest CDMO, Cell Solutions, and European assets Investing.com
Charles River Laboratories to divest CDMO, Cell Solutions and European discovery assets; updates 2026 guidance - TradingView
Charles River Laboratories to divest CDMO, Cell Solutions and European discovery assets; updates 2026 guidance TradingView
Charles River Laboratories to divest CDMO, Cell Solutions, and European assets - Investing.com
Charles River Laboratories to divest CDMO, Cell Solutions, and European assets Investing.com
Frequently Asked Questions About Charles River Laboratories
How many FDA inspections does Charles River Laboratories have on record?
CDMO Signal tracks 9 FDA inspections for Charles River Laboratories, sourced from the FDA inspection database. See the full inspection history above.
Has Charles River Laboratories received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Charles River Laboratories.
Does Charles River Laboratories hold EMA or MHRA GMP certificates?
CDMO Signal tracks 9 EMA and 2 MHRA GMP certificates for Charles River Laboratories.
What is Charles River Laboratories's CDMO Signal Score?
Charles River Laboratories has a Signal Score of 86/100, based on quality, operations, financial stability, and capacity data.
Evaluating Charles River Laboratories for a manufacturing program?
Use the free AI matchmaker to compare Charles River Laboratories against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 79.9
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
Rose BioSolutions
Rockville, MD · Memphis, TN · Keele, United Kingdom
Signal Score: 64.0
AAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 82.7
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody
Lonza
Basel, Switzerland
Signal Score: 72.8
AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation, Small Molecule API, High-Potency APIs, Oral Solid Dose
OmniaBio
Hamilton, ON
Signal Score: 61.5
AAV, Lentiviral, CAR-T, Cell Therapy
Compare Charles River Laboratories with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.